Tuesday, 25 September 2018

Connective Tissue Disease Market in depth study and analysis published, 2018

Market Scenario
Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
The specific cause of this disorder is unknown but the genetic patterns are considered to escalate the risk for developing connective tissue diseases. The connective tissue diseases arises due to changes in certain genes are often known as heritable disorders of connective tissue. Some of the common inherited disorders are Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), Marfan Syndrome, and Osteogenesis imperfect. EDS is an amalgamation of more than 10 disorders, characterized by stretchy skin, over-flexible joints, and abnormal growth of scar tissue. Various autoimmune diseases are also associated with connective tissue disorders, which includes polymyositis and dermatomyositis, rheumatoid arthritis (RA), Sjögren's syndrome, and vasculitis. Mixed connective tissue disease (MCTD) is another rare autoimmune disease, consisting of characteristic features of several diseases such as lupus, polymyositis or dermatomyositis, scleroderma, and rheumatoid arthritis. According to the National Center for Advancing Translational Medicines, currently there is no cure available for this condition but certain medications such as corticosteroids, immunosuppresive drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) help in the management of symptoms. It is also stated that MCTD is more frequent in females with a male to female ratio of 1:3, and the typical age of onset of MCTD is between 15-25 years.
Notably, the market is expected to expand in the near future due to the rising prevalence of various connective tissue disorders, high unmet needs of current treatment, and surge in the research and development expenditure.
Despite these drivers, there are some issues associated with connective tissue disease market. Lack of infrastructure in the middle and low income countries may hamper the growth of the market.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
Intended Audience
  • Hospitals
  • Diagnostic clinics
  • Research and Development (R&D) Companies
  • Government Research Institute
  • Academic Institutes and Universities 
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Key Players
Some of key the players in the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Pfizer, AutoImmune Inc., Johnson & Johnson, Amgen Inc., AstraZeneca, Eli Lilly and Company, Biogen, LUPIN, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Latest Study Offers Detailed Insights on Electronic Pill Market 2018

Market Scenario
The global electronic pill market is expected to reach an approximate CAGR of 15% during the forecast period. The electronic pill is an ingestible capsule that is embedded with sensors and camera. After ingesting the pill, the pill captures several images per second of the gastrointestinal tract which is received by the connected recording device. It is a monitoring system used to monitor temperature, pH, conductivity and dissolved oxygen. Electronic Pills are used for diagnostics of various gastrointestinal tract diseases like colon cancer, colon polyps, gastrointestinal bleeding and other infectious diseases. The increase in preference of non-invasive methods for diagnostics is driving the growth of the market. Moreover, the rising geriatric population, increasing prevalence of gastrointestinal diseases like colorectal cancer, changing lifestyle, increasing unhealthy eating habits, controlled drug delivery and better way of endoscopy procedures are major factors influencing the growth of the market.
According to the American Cancer Society, Inc. in 2017, 27,150 men and 23,110 women had colorectal cancer in the US. Thus, such a high incidence rate of colorectal cancer provides favorable backgrounds for the market growth. Also, growing demand for rapid and precise diagnostics, adoption of advanced technology are the key factors for the market to grow.
However, factors such as bowel obstruction, lack of awareness, capsule retention and high costs are expected to restrict the market growth during the forecast period.
Segmentation
The global electronic pill market is segmented on the basis of Application, Target area, Parts and end user. The electronic pill market, by application, is sub-segmented into Capsule Endoscopy, Drug Delivery, and Patient Monitoring. Target area category includes Oesophagus, Stomach, Small Intestine, and large intestine.
By parts, the market is categorized into biocompatible capsule encasing microsensors, Control chip, Radio transmitter and Power source. On the basis of end-user, the market is segmented into Hospitals, Diagnostic centers, Clinical Research Organizations and Medical Centers.
On the basis of region, the global Electronic Pill market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Global Electronic Pill Market, by Key Players
  • CapsoVision, Inc. (US),
  • Given Imaging Ltd. (Israel),
  • Medimetrics (Mexico),
  • Bio-Images Drug Delivery BDD LTD (UK),
  • Proteus Digital Health (US),
  • Olympus Corporation,
  • Medtronic,
  • Medisafe,
  • JINSHAN Science & Technology,
  • INTROMEDIC
Regional Market Summary
The Electronic Pill market is dominated by North America owing to rising prevalence of gastrointestinal disorders and high R&D investments within this region stimulate market growth. According to the US Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of gastrointestinal disorders influences the market growth in this region.
It is estimated that Europe stood second in the global Electronic Pill market. The increasing prevalence of gastric cancer is driving the growth of this market in Europe. According to the Cancer Research UK in 2015, 6740 new cases of stomach cancer in the U.K and is among the most common prevalent cancer. Thus, increasing prevalence of gastric cancer in Europe drives the market growth. Furthermore, the rapidly growing healthcare sector in Europe is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the global Electronic Pill market. Key factors such as rising geriatric population, growing patient pool, high incidence of gastrointestinal diseases and developing healthcare infrastructure drive the market in this region. According to the Asian Development Bank (ADB), the geriatric population in Asia is expected to reach 923 million by 2050. This provides favorable backgrounds for the market to grow.
The Middle East and Africa holds the least share in the global Electronic Pill market due to the presence of stringent government policies and poor economic growth. However, growing awareness and increasing investment by private market players in this region can boost the market growth. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cell Therapy Market Top Trends, Regulations and Competitive Landscape Outlook To 2023

Market Scenario
Cell therapy has come forward as a recent phase of the biotechnology revolution in medical sector. As cell therapy is based on ground-breaking scientific discoveries and various technological advancements. The main aim of cell therapy is to target various diseases at the cellular level by restoring a certain cell population as carriers of therapeutic cargo. It is also used in combination with gene therapy for many diseases. For many diseases, gene and cell therapy are applied in combination.
With new technologies, and different types of cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, skeletal muscle stem cells, lymphocytes, pancreatic islet cells, and dendritic cells, cell therapy can be used for the treatment of a variety of diseases. Hematopoietic stem cell transplantation or Bone marrow transplant is the most commonly used cell therapy to treat a variety of hematologic conditions and blood cancers. Potential applications of cell therapy include treatment of cancers, urinary problems, autoimmune disease, and infectious disease, repairing spinal cord injuries, rebuilding damaged cartilage in joints, improving the immune system, and treatment of neurological disorders.
Adipose tissue-derived stem cells (ADSCs) are another most promising cell types for application in regenerative therapies. Regenerative medicine is an interdisciplinary field comprises of tissue engineering, with an objective of restoration or establishment of the normal functioning of organs.
Around the world stem cell therapy, and related products are being regulated by various guidelines and laws based on the regulatory agencies in charge, i.e. the Food and Drug Administration (FDA) in the USA, the European Medicines Agency (EMA) in Europe, different and other regional authorities. According to a study published in Transfusion Medicine and Hemotherapy in 2016, it is found that the therapeutic products based on gene therapy, and somatic cell therapy are defined as advanced therapy medicinal products (ATMP), in Europe.
Notably, rising prevalence of chronic disorders is the key factor driving the cell therapy market. According to a study published in Neurology India journal in 2014, it is found that out of total population of India, around 30 million people were suffering from neurological disorders.
Various other push factors such as increasing geriatric population, increasing government assistance, replacement of animal testing model, technological advancements, and improvement in regulatory framework continuously contribute to the growth of the global cell therapy market. As per the instructions suggested by the FDA on the regulation of tissue engineering, the purity and quality of engineered tissue should be maintained and regulated to avoid any kind of chemical instability.
Despite these drivers, there are some issues associated with cell therapy market. Challenges in research and development, the high cost of manufacturing, and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
It is estimated that cell therapy market is expected to grow at a CAGR 10.6% during the forecast period of 2017-2023.
Intended Audience
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Regenerative medicine centers
  • Government Research Institute
  • Academic Institutes and Universities
Segmentation
The cell therapy market is segmented on the basis of type, technology, cell source, application, and end-user.
On the basis of type, the market is segmented into autologous, and allogeneic.
On the basis of technology, the market is classified into somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Viral vector technology is further segmented into Ex vivo gene modification of cells and In vivo gene modification of cells.
On the basis of cell source, the market is classified into induced pluripotent stem cells (iPSCs), bone marrow, umbilical cord blood-derived cells, adipose tissue, and neural stem cell.
On the basis of application, the market is classified into musculoskeletal, cardiovascular, gastrointestinal, neurological, oncology, dermatology, wounds and injuries, ocular, and others.
On the basis of end-users, the market is segmented into hospital & clinics, regenerative medicine centers, diagnostic centers, research institutes, and others.
Regional Analysis
The Americas dominate the cell therapy market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in cell therapy market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
The Asia Pacific is the fastest growing cell therapy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014–15.
The Middle East & Africa has the lowest market for cell therapy due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the cell therapy market are Novartis AG, GlaxoSmithKline plc, MEDIPOST, Osiris, PHARMICELL, NuVasive, Inc., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO.,LTD., Cynata, CELLECTIS, BioNTech IMFS, EUFETS GmbH, Cognate, Pluristem, Grupo Praxis, Genzyme Corporation, Advanced Tissue and others. 

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Keratoconus Treatment Market 2018–By Identifying the Key Market Segments and Key players holding market share

Market synopsis of global keratoconus treatment market:
Market Scenario:
Keratoconus is a progressive eye disorder. In this condition, cornea thins and begins to bulge outward into a cone-like shape and causes distorted or blurred vision, increased sensitivity to bright light or glare, sudden clouding of vision etc.
Development of technologically advanced diagnostic and treatment products, growing awareness, increasing healthcare expenditure, and rising demand from emerging regions are driving the growth for global keratoconus treatment market.
Globalkeratoconus treatment market is expected to grow at the CAGR of ~4.1% during the forecast period and is estimated to reach USD 427.5 million by 2023.
Study objectives of global keratoconus treatment market:
  • To provide detailed analysis of the global keratoconus treatment market structure with historical and forecast revenue for the next six years of the various segments and sub-segments.
  • To provide insights about the key drivers, restraints, opportunities and challenges affecting the growth of global keratoconus treatment market
  • To provide analysis of the market with respect to various countries in the four main geographies– the Americas, Europe, Asia Pacific, and Middle East & Africa.
  • To provide detailed analysis of the market segmented by type, diagnosis, treatment, end user, and its sub-segments.
  • To provide a detailed analysis of global keratoconus treatment market mainly based on Value Chain Analysis, Porter’s Five Forces, Price Analysis, and Supply Chain Analysis etc.
  • To provide a detailed country level analysis of the market with respect to the current market size and future prospects.
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global keratoconus treatment market.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the keratoconus treatment market.
Intended Audience:
  • Keratoconus medicines manufacturers
  • Keratoconus medicines and treatment providers
  • Hospitals and clinics
  • Medical Research laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments:                                                                                                                                        
Global keratoconus treatment market has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others.
On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others.
On the basis of treatments, the market has been segmented into lenses, surgery, collagen cross-linking, and others. Lenses is sub-segmented into eyeglasses or soft contact lenses, hard contact lenses, piggyback lenses, hybrid lenses, scleral lenses, and others. Surgery is sub-segmented into corneal inserts, cornea transplant, and others. Collagen cross-linking is still in research process and more study is required to implement this treatment option.
On the basis of end user, it is segmented into eye hospitals & clinics, medical research centers, academic institutes, and others.
Regional analysis of global keratoconus treatment market:                 
Considering the global scenario of the market, America is the highest revenue generator with North American region contributing the most. North America mainly includes US and Canada. US is one of the dominant markets not only in America but also in the global market. European market is the second largest and UK is believed to be the fastest growing market for keratoconus treatment in this region. Increasing awareness, growing purchasing power, and rapidly improving healthcare sector are driving the growth for Asia Pacific keratoconus market. Asia Pacific is one of the high potential market for keratoconus treatment. Due to slow adoption of new treatments and prosucts, Middle East and Africa is expected to grow at steady pace.
Key players for global keratoconus treatment market:                               
Some of the key players in this market are: Bausch & Lomb Incorporated (US), CIBA VISION (US), CooperVision (US), HOYA Vision Care (Singapore), Johnson & Johnson Vision Care, Inc. (US), Menicon Co., Ltd. (Japan), Novartis AG (Switzerland), Optik Seis (Indonesia), and SAFILENS S.R.L. (Italy), and others.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Nasal Drug Delivery Market Segmentation Detailed Study with Forecast Up To 2018-2023

Market Synopsis of Middle East and Africa Nasal Drug Delivery Market:
Market Scenario:
The intra-nasal route of drug administration is becoming popular due to its noninvasive nature thereby reducing pain and threat of infections and allows the patient to self-administer drugs without any help from anyone. Moreover recent research has also pointed its applications related to drug delivery to the brain. Bioavailability of a drug is defined as the proportion of a drug entering the systemic circulation as compared to the dosage. Nasal drug delivery eliminates drug destruction by HCL present in the stomach thereby increasing bioavailability which reduces the dosage of the drug. The reduction in dosage leads to proportional reduction in side effects. Growth of over the counter nasal drugs such as inhalers for common cold is also driving the market.
The market for nasal drug delivery is increasing at a good CAGR due to the above mentioned advantages of nasal drugs.  Other market driving factors include ease of administration, growing efficacy of the route due to development of drugs which are absorbed easily from the nasal route and the development of advanced products such as metered dose pressurized containers which deliver a very precise dose.
The market’s constraints are irritation of the nasal route and the low dose of the drug that can be delivered as compared to other route of administration. Other constraints includes low awareness and concurrent low popularity of the route which reduces economies of scale in producing these delivery devices. The market for nasal drug delivery has oligopolistic characteristic due to a few dominant players. Thus the power of the sellers is high and there is a premium on most nasal drug delivery products.
Taking all factors into consideration, we expect the Middle East and Africa nasal drug delivery market to reach around $ 1.59 billion in 2022 growing at a CAGR of 8.1%; this market was worth $ 1 billion in 2015.
Study Objectives Middle East and Africa Nasal drug delivery Market:
  • To provide detail analysis of the market structure along with forecast for the next 6 years of various segments and sub-segments of the Middle East and Africa nasal drug delivery market.
  • To provide insights about factors affecting the market growth.
  • To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
  • To provide past and estimated future revenue of the Middle East and Africa nasal drug delivery market’s segments and sub-segments.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide country level analysis of the market for segments which includes by dosage form, by system, by delivery technologies, by therapeutic applications and other sub segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market.
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments globally.
Intended Audience
  • Nasal drug delivery device manufacturers
  • Nasal drug delivery device suppliers
  • Private research laboratories
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Government research laboratories
  • Contract manufacturing organizations
Key Players for Middle East and Africa Nasal Drug Delivery Market
Some of the key players in this market are Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., AptarGroup Inc., Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Becton Dickson & Company and others.
Segments:
Middle East and Africa nasal drug delivery market has been segmented on the basis of dosage form which comprises of drops, sprays, powder, gels and ointments. On the basis of system, market is segmented into unit dose, multi-dose and metered dose. On the basis of delivery technologies; market is segmented into spray, nebulizers and other. On the basis of therapeutic applications; market is segmented into rhinitis, congestion, vaccinations and others.
Regional Analysis of Middle East and Africa Nasal drug delivery Market:
UAE is the largest market for nasal drug delivery in entire Middle East and Africa nasal drug delivery Market closely followed by Egypt. The rest of Africa’s market is growing at a very fast rate due to huge unmet medical needs and growing popularity of nasal route.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Latest Study Offers Detailed Insights on India CRO Market 2018

Market Synopsis of India CRO Market:
Market Scenario:
A contract research organization (CRO) provides support to the pharmaceutical, biotechnology, and medical device industries for specific services on a contract basis. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals
The other factors favoring the market are efforts by the regulatory authorities such as Director Controller General of India (DCGI), Indian Council of Medical Research (ICMR), Directorate General of Foreign Trade (DGFT), Department of Biotechnology (DBT) to create an amenable climate for research in India.
The market constraints are growing concern for security especially data security and patient security, lack of collaboration between universities and industry etc. The compromises done by some Indian CROs on ethical and technical standards are the greatest market threat.
Taking all factors into consideration, we expect the India CRO market to reach around $1973.82 million from $1000 million in 2016, by the end of the forecast period at a CAGR of ~12.00%.
Study Objectives India CRO Market:
  • To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Indian CRO market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments for India CRO market
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by service type, by therapeutic applications, by end users and other sub segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.
Key Players for India CRO Market: 
Some of the key players in this market are: Quintiles IMS Holdings, Inc., Pharmaceutical Product Development, Siro Clinpharm, GVK Bio, Clininvent, CliniRX Tangent Research, Ecron Acunova, Ace Biomed Pvt. Ltd., Actimus Biosciences Pvt. Ltd., Alkem Laboratories Ltd., Actis Biologics Pvt Ltd. and others.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The healthcare sector of India is divided between differential geographic regions and states. The South India and western India account for a major share of the Indian CRO market. However of late the CRO industry is shifting to the North. The reasons for this shift is the concentration of regulatory authority such as Director Controller General of India (DCGI) office, Indian Council of Medical Research (ICMR), Directorate General of Foreign Trade (DGFT), Department of Biotechnology (DBT) etc. Also the costs are lower in North India and the genetic pool is more diverse.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Monday, 24 September 2018

Acute Hospital Care Market 2018 Analysis, Opportunities and Forecast to 2023

Market ScenarioAcute care is a branch of health care in which short-term treatment is provided to patients with medical conditions such as severe injury and recovery from surgery. Acute conditions such as asthma attack, broken bone, bronchitis, burn, common cold, flu, heart attack, pneumonia, and others require treatment in acute hospital care. Various services are included in acute hospital care such as coronary care, intensive care, neonatal intensive care, cardiology, and others. The acute care market growth is majorly attributed due to the rising incidences of trauma injury, the presence of a large base of the patient population, increasing number of hospital, unmet medical needs in emerging economies. Moreover, the geriatric population having acute diseases are projected to boost the market growth over the forecast period.
According to the American Academy of Allergy, Asthma & Immunology, during 2011-2014, asthma prevalence was 8.8% among all adults. During this period, asthma was more common among adults with obesity (11.1%) compared with adults in normal weight (7.1%) and overweight (7.8%) people.
As per reports from American Academy of Orthopedic Surgeon, broken bones are a common injury i.e an average of 6 million people in the U.S is likely to break a bone each year. Most of these broken bones heal without problems. However, about 300,000 patients are slow to heal or do not heal at all with traditional methods. Since broken bone is a common problem, it needs acute hospital care, Therefore,  it is estimated to fuel the market growth during the forecast period.

However, limited availability of facilities and equipment may hamper the market growth during the forecast period.
The global acute hospital care market is expected to grow at a CAGR of ~7.8% during the forecast period 2017-2023. 
Intended Audience
  • Pharmaceutical and Biotechnological Companies
  • Research and Development (R&D) Companies
  • Ambulatory Care Centers
  • Hospitals and Clinics
  • Academic Institutes and Universities
  • Market Research and Consulting Service Providers
  • Potential Investors 
Segmentations
The global acute hospital care market is segmented on the basis of medical condition and services.
On the basis of the medical condition, it is segmented into emergency care, urgent care, short-term stabilization, pre-hospital care, critical care, trauma care, and acute care surgery.  
On the basis of the services, it is segmented into coronary care, intensive care, neonatal intensive care, cardiology, and emergency department.
Regional AnalysisThe Americas dominate the global acute hospital care market owing to well-developed technology, increasing patient population, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global acute hospital care market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.   
Asia Pacific is the fastest growing acute hospital care market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for acute hospital care in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa. 
Key Players
Some of key the players in the market are HCA Holdings, Inc. (U.S.), Community Health Systems LLC (U.S.), Universal Health Services, Inc. (U.S.), Tenet Healthcare Corp. (U.S.), Vanguard Health System Inc. (U.S.), Ardent Health Services (U.S.), Kindred Healthcare, Inc. (U.S.), PruittHealth (U.S.), National HealthCare Corp.(U.S.), and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Comments (Atom)